Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Change in Accured Expenses (2021 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Change in Accured Expenses for 5 consecutive years, with -$2.4 billion as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 492.1% to -$2.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$441.0 million through Dec 2025, down 129.72% year-over-year, with the annual reading at -$441.0 million for FY2025, 129.72% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$2.4 billion at Bristol Myers Squibb, down from $1.7 billion in the prior quarter.
  • The five-year high for Change in Accured Expenses was $1.8 billion in Q3 2024, with the low at -$2.4 billion in Q4 2025.
  • Average Change in Accured Expenses over 5 years is $161.8 million, with a median of $88.0 million recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 141.86% in 2022, while the deepest fall reached 676.92% in 2022.
  • Over 5 years, Change in Accured Expenses stood at -$39.0 million in 2021, then plummeted by 676.92% to -$303.0 million in 2022, then surged by 30.36% to -$211.0 million in 2023, then crashed by 91.94% to -$405.0 million in 2024, then tumbled by 492.1% to -$2.4 billion in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$2.4 billion, $1.7 billion, and $881.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.